Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (71)	10/21/2005 2:36:33 PM
From: tuck	Read Replies (2) \| Respond to of 318

[Looks like DSCO has a new PDUFA date: next April] >>WARRINGTON, Pa., Oct. 21, 2005 (PRIMEZONE) -- Discovery Laboratories, Inc. (NasdaqNM:DSCO - News) has been informed today by the U.S. Food and Drug Administration (FDA) that the FDA has accepted Discovery's resubmission of October 5, 2005 as a complete response to the Approvable Letter for Surfaxin(R), for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA has established April 2006 as its target to complete its review of the Surfaxin New Drug Application (NDA). Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, commented, ``With the acceptance of our response to the Surfaxin Approvable Letter, the FDA six-month review process has begun as of October 5, 2005, the date of our resubmission. Discovery will work diligently with the FDA during this review, which will include the reinspection of our Surfaxin contract manufacturing facility, Laureate Pharma in Totowa, New Jersey. We anticipate that Surfaxin, the first precision-engineered Surfactant Replacement Therapy, will be available to the neonatal medical community in the second quarter of 2006.'' Surfaxin is a precision-engineered, peptide-containing, synthetic surfactant that is designed to closely mimic the function of natural human lung surfactant and represents a potential alternative for the animal-derived and non-protein containing synthetic surfactants. Discovery's Surfaxin has received an Approvable Letter from the FDA for the prevention of RDS in premature infants and is pending approval. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. Premature babies are born with a lack of natural surfactant in their lungs. Without surfactant, the air sacs in the lungs collapse and are unable to absorb sufficient oxygen resulting in RDS.<< snip Stock is up a good chunk at the moment, 12%. Cheers, Tuck